Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

AVEO Announces Proposed Public Offering of Common Stock



  AVEO Announces Proposed Public Offering of Common Stock

Business Wire

CAMBRIDGE, Mass. -- January 16, 2013

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that it has
commenced an underwritten public offering of shares of its common stock. All
of the shares in the offering are to be sold by AVEO.

J.P. Morgan Securities LLC is acting as sole book-running manager for the
proposed offering, with RBC Capital Markets, LLC and Canaccord Genuity Inc.
acting as co-lead managers. AVEO intends to grant the underwriters a 30-day
option to purchase up to an additional 15 percent of the amount of shares sold
in the offering to cover over-allotments, if any. The offering is subject to
market and other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of the
offering.

A shelf registration statement on Form S-3 relating to the public offering of
the shares of common stock described above was filed with the Securities and
Exchange Commission (the “SEC”) and is effective. A preliminary prospectus
supplement relating to the offering has been filed with the SEC. Copies of the
preliminary prospectus supplement and accompanying prospectus may be obtained
from the offices of J.P. Morgan Securities LLC, c/o Broadridge Financial
Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 (Telephone number
866-803-9204).

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of any such state or other
jurisdiction.

About AVEO

AVEO (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering,
developing and commercializing targeted therapies to impact patients’ lives.
AVEO Pharmaceuticals, Inc. conducts business as AVEO Oncology.

Forward-Looking Statements

Certain of the statements made in this press release are forward-looking, such
as those, among others, relating to our expectations regarding the completion
of the proposed public offering. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include, without
limitation, risk and uncertainties related to whether or not we will be able
to raise capital through the sale of shares of common stock, the final terms
of the proposed offering, market and other conditions, the satisfaction of
customary closing conditions related to the proposed public offering and the
impact of general economic, industry or political conditions in the United
States or internationally. There can be no assurance that we will be able to
complete the proposed public offering on the anticipated terms, or at all. You
should not place undue reliance on these forward-looking statements, which
apply only as of the date of this press release. Additional risks and
uncertainties relating to the proposed offering, AVEO and our business can be
found under the heading “Risk Factors” included in AVEO’s current report on
Form 8-K filed with the SEC on January 16, 2013 and in the preliminary
prospectus supplement related to the proposed offering filed with the SEC on
or about the date hereof, and in other filings that AVEO periodically makes
with the SEC. In addition, the forward-looking statements included in this
press release represent our views as of the date of this press release. We
anticipate that subsequent events and developments will cause our views to
change. However, while we may elect to update these forward-looking statements
at some point in the future, we specifically disclaim any obligation to do so.
These forward-looking statements should not be relied upon as representing our
views as of any date subsequent to the date of this press release.

Contact:

Investor Contact:
AVEO Oncology
Monique Allaire, 617-299-5810
or
Media Contact:
Rob Kloppenburg, 617-299-5655
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement